A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles

Şekerdağ, Emine; Lüle, Sevda; Pehlivan, Sibel Bozdağ; Öztürk, Naile; Kara, Aslı; Kaffashi, Abbas; Vural, İmran; Işıkay, İlkay; Yavuz, Burçin; Oğuz, Kader K.; Söylemezoğlu, Figen; Gürsoy‐Özdemir, Yasemin; Mut, Melike

doi:10.1016/j.jconrel.2017.06.032

Cited by 50 publications

(35 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration than by i.v. even though the dose was 10 times smaller; intranasally administered nanoparticles could reach peripheral organs after redistribution from the CNS to the systemic circulation [ 52 , 53 ]. These results highlight the benefit of i.n.…”

Section: Resultsmentioning

confidence: 99%

Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study

2020

View full text Add to dashboard Cite

Intranasal (i.n.) administration became an alternative strategy to bypass the blood–brain barrier and improve drug bioavailability in the brain. The main goal of this work was to preliminarily study the biodistribution of mixed amphiphilic mucoadhesive nanoparticles made of chitosan-g-poly(methyl methacrylate) and poly(vinyl alcohol)-g-poly(methyl methacrylate) and ionotropically crosslinked with sodium tripolyphosphate in the brain after intravenous (i.v.) and i.n. administration to Hsd:ICR mice. After i.v. administration, the highest nanoparticle accumulation was detected in the liver, among other peripheral organs. After i.n. administration of a 10-times smaller nanoparticle dose, the accumulation of the nanoparticles in off-target organs was much lower than after i.v. injection. In particular, the accumulation of the nanoparticles in the liver was 20 times lower than by i.v. When brains were analyzed separately, intravenously administered nanoparticles accumulated mainly in the “top” brain, reaching a maximum after 1 h. Conversely, in i.n. administration, nanoparticles were detected in the “bottom” brain and the head (maximum reached after 2 h) owing to their retention in the nasal mucosa and could serve as a reservoir from which the drug is released and transported to the brain over time. Overall, results indicate that i.n. nanoparticles reach similar brain bioavailability, though with a 10-fold smaller dose, and accumulate in off-target organs to a more limited extent and only after redistribution through the systemic circulation. At the same time, both administration routes seem to lead to differential accumulation in brain regions, and thus, they could be beneficial in the treatment of different medical conditions.

show abstract

Section: Resultsmentioning

confidence: 99%

Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study

2020

View full text Add to dashboard Cite

show abstract

“…In addition, non-conventional systemic administration routes may be investigated to specifically accumulate drugs to cellular or tissue targets. Particularly, non-invasive intranasal administration may be exploited for the nose-to-brain delivery, circumventing the first passage in the liver and the blood-brain barrier, thus increasing the fraction of drug at the target site [132,133]. On the other hand, intraperitoneally injection proved to be effective in targeting circulating macrophages, which, once repolarized, exhibited inherent tumor tropism [134].…”

Section: Optimizing the Administration Routementioning

confidence: 99%

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

Salvioni

Rizzuto

Bertolini

et al. 2019

Cancers

148

138

View full text Add to dashboard Cite

Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.

show abstract

“…However, after IN administration the highest accumulation of NPs was detected in the olfactory bulb, whereas following IV administration the nanocarrier caused a high accumulation of FTA in the spleen and liver (Fig. 3B) [122].…”

Section: Drug Delivery Systems For Nose-to-brain Delivery In Glioblasmentioning

confidence: 93%

“…In a similar study, another group developed a polymeric NP formulation of carboplatin (CPC) using the biodegradable polymer poly(ε-caprolactone) [128]. Another group worked on lipid-PEG-PLGA hybrid nanoparticles (HNP) for intranasal delivery of FTA with the aim to increase the brain-targeting efficacy of farnesyl thiosalicylic acid [122].…”

Section: Drug Delivery Systems For Nose-to-brain Delivery In Glioblasmentioning

confidence: 99%

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Bruinsmann¹,

Vaz²,

Alves³

et al. 2019

Preprint

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most lethal form of brain tumor, characterized by rapid growth and surrounding tissue invasion. The current standard treatment is surgery followed by radiotherapy, and concurrent chemotherapy, typically with temozolomide. Although extensive research has been performed over the past years to develop an effective therapeutic strategy for the treatment of GBM, efforts have not provided major improvements in the overall survival of patients with GBM. Thus, new therapeutic approaches are urgently needed. A major challenge in the development of therapies for central nervous system (CNS) disorders is overcoming the blood–brain barrier (BBB). In this context, the intranasal (IN) route of drug administration has been proposed as a non-invasive alternative route to directly targeting the CNS. In fact, this route of drug administration may bypass the blood-brain barrier and reduce systemic side effects. Recently, formulations have been developed to further enhance nose-to-brain transport, mainly with the use of nano-sized and nanostructured drug delivery systems. The focus of this review will be on the strategies developed to deliver a number of anticancer compounds for the treatment of GBM using the nasal administration. In particular, the specific properties of nanomedicines proposed for the nose-to-brain delivery will be critically evaluated. The number of preclinical and clinical data reviewed support the idea that nasal delivery of anticancer drugs might represent a breakthrough advancement in the fight against GBM.

show abstract

A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles

Cited by 50 publications

References 51 publications

Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study

Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study

Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Contact Info

Product

Resources

About